Elvanse® (lisdexamfetamine dimesylate) receives UK marketing authorisation for the treatment of ADHD in children and adolescents
Source: Shire plc
Area: News
The MHRA has granted a marketing authorisation to Shire plc for Elvanse® (lisdexamfetamine dimesylate) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. Lisdexamfetamine is a once daily long-acting prodrug stimulant, which is due to be launched in the UK at the beginning March (further details on formulations, cost, dosing etc will not be available untill product launch).
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news
More News: ADHD | Children | Concerta | Health | Hyperactivity | Marketing | Men | Methylphenidate | Psychiatry | Ritalin | Vyvanse